Insulet’s (PODD) Outperform Rating Reiterated at Royal Bank Of Canada

Insulet (NASDAQ:PODD)‘s stock had its “outperform” rating reiterated by equities research analysts at Royal Bank Of Canada in a report released on Wednesday,Benzinga reports. They presently have a $280.00 price target on the medical instruments supplier’s stock. Royal Bank Of Canada’s price objective indicates a potential upside of 94.41% from the stock’s current price.

Several other research analysts have also recently issued reports on the company. Bank of America cut their target price on Insulet from $288.00 to $208.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. Truist Financial reduced their target price on shares of Insulet from $315.00 to $250.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Benchmark started coverage on shares of Insulet in a report on Tuesday, May 12th. They issued a “buy” rating for the company. Barclays cut their price target on shares of Insulet from $286.00 to $198.00 and set an “underweight” rating on the stock in a report on Thursday, May 7th. Finally, Robert W. Baird reduced their price objective on shares of Insulet from $360.00 to $248.00 in a research report on Thursday, May 7th. Twenty-one analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $252.48.

Insulet Stock Down 6.4%

Shares of Insulet stock traded down $9.78 during trading hours on Wednesday, reaching $144.03. The company’s stock had a trading volume of 627,610 shares, compared to its average volume of 1,134,362. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49. The stock’s fifty day simple moving average is $188.59 and its two-hundred day simple moving average is $248.51. The company has a market capitalization of $9.98 billion, a P/E ratio of 33.49, a P/E/G ratio of 1.23 and a beta of 1.20. Insulet has a one year low of $141.02 and a one year high of $354.88.

Insulet (NASDAQ:PODD) last posted its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. The company had revenue of $761.70 million for the quarter, compared to analyst estimates of $729.89 million. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The firm’s revenue was up 33.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.02 EPS. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, research analysts forecast that Insulet will post 6.43 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PODD. Glenmede Investment Management LP raised its holdings in shares of Insulet by 1.6% in the 3rd quarter. Glenmede Investment Management LP now owns 2,292 shares of the medical instruments supplier’s stock worth $708,000 after purchasing an additional 35 shares during the period. Curi Capital LLC increased its position in Insulet by 0.8% in the second quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier’s stock worth $1,365,000 after buying an additional 36 shares during the last quarter. WINTON GROUP Ltd raised its stake in shares of Insulet by 0.9% in the third quarter. WINTON GROUP Ltd now owns 4,086 shares of the medical instruments supplier’s stock valued at $1,261,000 after buying an additional 37 shares during the period. Great Lakes Advisors LLC lifted its position in shares of Insulet by 1.5% during the 4th quarter. Great Lakes Advisors LLC now owns 2,784 shares of the medical instruments supplier’s stock valued at $791,000 after buying an additional 40 shares during the last quarter. Finally, Camarda Financial Advisors LLC lifted its position in shares of Insulet by 0.5% during the 2nd quarter. Camarda Financial Advisors LLC now owns 7,332 shares of the medical instruments supplier’s stock valued at $2,304,000 after buying an additional 40 shares during the last quarter.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.